Gliclazide (Diabefarm MR) XR 30 mg – [60 tablets]

Description

Diabefarm Pharmacodynamics
Diabefarm® MB is an oral hypoglycemic drug, sulfonylurea derivative of II generation. It stimulates insulin secretion (3-cells of the pancreas, increases insulin-secreting action of glucose, increases sensitivity of peripheral tissues to insulin. Stimulates the activity of intracellular enzymes – muscle glycogen synthetase. Shortens the interval from the moment of food intake to the beginning of insulin secretion. Restores the early peak of insulin secretion (unlike other sulfonylurea derivatives that affect mainly during the second stage of secretion). Reduces postprandial glucose elevation
In addition to its effect on carbohydrate metabolism, it improves microcirculation: it reduces platelet adhesion and aggregation, normalizes vascular permeability, prevents the development of microthrombosis and atherosclerosis, and restores the process of physiological parietal fibrinolysis. Reduces the sensitivity of vascular receptors to adrenaline. Slows down the development of diabetic retinopathy at nonproliferative stage. In diabetic nephropathy against the background of long-term use causes a significant reduction in the severity of proteinuria. Does not lead to weight gain, since it has a predominant effect on the early peak of insulin secretion and does not cause hyperinsulinemia; promotes weight loss in obese patients with an appropriate diet.

Indications
Diabetes mellitus type 2 in combination with diet therapy and moderate physical activity in the ineffectiveness of the latter.

Contraindications
– Hypersensitivity to the drug;
– diabetes mellitus type 1;
– diabetic ketoacidosis, diabetic precoma, diabetic coma; – hyperosmolar coma;
– severe hepatic and/or renal insufficiency;
– major surgical interventions, extensive burns, injuries and other conditions requiring insulin therapy; intestinal obstruction, gastric paresis;
– conditions accompanied by impaired absorption of food, development of hypoglycemia (infectious diseases);
– leukopenia;
– pregnancy,
– Breast-feeding period;
– Children under 18 years of age.
With caution:
With caution (need for closer supervision and dose selection) administer Diabefarm® MV in febrile syndrome, alcoholism and diseases (thyroid gland (with impaired thyroid function), elderly people.

Dosage and administration

• Dosage of drug should be adjusted individually depending on clinical manifestations of disease, glucose level on an empty stomach and 2 hours after meal. Usually initial daily dose (including for elderly people over 65 years old) is 30 mg (1 tablet), further on, if necessary, the drug dose is increased with an interval of not less than 2 weeks.
• Maximum daily dose is 120 mg (4 pills). The drug is taken orally once a day in the morning, during breakfast.
• Diabefarm® MB can replace Diabefarm in doses of 1 to 4 tablets per day.
  It can be used in combination with other hypoglycemic agents: biguanides, alpha-glucosidase inhibitors or insulin
• In patients with mild to moderate renal dysfunction (creatinine clearance from 15 to 80 ml/min), the drug is prescribed in the same dosage.